local_hospital

UMCG

Address
lock Available on a paid plan

Neurology and Nervous System Diseases

At UMCG in Groningen, clinical research in Neurology focuses strongly on Parkinson’s disease and Alzheimer’s disease, with studies also touching on intracerebral haemorrhage and other brain disorders. The trials are exploring new treatment options, assessing safety and tolerability, and looking at whether therapies can better support brain function and patient outcomes.

  • Studies in Parkinson’s disease are evaluating potential therapies aimed at symptom control and disease-related brain changes.
  • Research in Alzheimer’s disease is examining safety and early signs of treatment benefit in people with cognitive decline.
  • Work on intracerebral haemorrhage is testing ways to improve recovery and reduce later vascular complications.

The site’s neurology portfolio reflects a mix of treatment development and clinical evaluation, with a clear emphasis on disorders that affect movement, memory, and brain injury.

Cardiovascular Diseases and Investigative Techniques

Clinical trials at UMCG include research in Cardiovascular Diseases that targets STEMI and stroke-related complications after brain bleeding. Several studies are also using advanced imaging and diagnostic approaches to better understand inflammation and treatment response, supporting more precise care in cardiovascular and cerebrovascular disease.

  • Trials in STEMI are exploring new ways to reduce heart muscle injury and improve recovery after acute events.
  • Research following intracerebral haemorrhage is focused on preventing later vascular events and improving long-term outcomes.
  • Investigative Techniques are being used to measure inflammation and identify markers that may guide treatment decisions.

This area combines therapeutic testing with diagnostic innovation, aiming to make cardiovascular and cerebrovascular care more effective and better targeted.

Immune System Diseases and Musculoskeletal Diseases

The research landscape at UMCG also includes trials in Immune System Diseases and Musculoskeletal Diseases, especially giant cell arteritis and rheumatoid arthritis. These studies are examining inflammation in blood vessels and joints, with the goal of improving diagnosis, understanding disease activity, and supporting more effective treatment choices.

  • Giant cell arteritis studies are using imaging to detect inflamed arteries and track disease activity.
  • Rheumatoid arthritis research is looking at joint inflammation and how it can be measured more accurately.
  • Some projects are also investigating immune-related side effects linked to cancer immunotherapy.

These trials highlight a strong interest in inflammatory disease, where better detection and clearer understanding of immune responses may lead to improved patient care.

Neoplasms and cancer-related care

In the area of Neoplasms, the site is involved in studies related to glioblastoma, non-small cell lung cancer, and broader cancer care. The research includes efforts to refine surgery, understand treatment-related immune effects, and evaluate new approaches that may improve safety and effectiveness for people with cancer.

  • Glioblastoma research is focused on improving tumor visualization during surgery.
  • Non-small cell lung cancer and other cancer studies are examining immune-related complications from treatment.
  • Some trials are designed to better define how cancer therapies affect the nervous and rheumatologic systems.

This cancer portfolio combines therapeutic innovation with translational research, aiming to make treatment more precise and easier to monitor.

Digestive System Diseases and Male Urogenital Diseases

Additional trials at UMCG cover Digestive System Diseases and Male Urogenital Diseases, including advanced liver fibrosis and cirrhosis and erectile dysfunction. These studies are evaluating new therapies and helping clarify whether treatments can improve organ function and quality of life.

  • Research in advanced liver fibrosis and cirrhosis is aimed at understanding disease progression and treatment response.
  • Trials in erectile dysfunction are testing a potential therapy for safety and effectiveness.
  • Some studies also include healthy volunteers to support early assessment of how new medicines behave in the body.

These projects broaden the site’s clinical trial activity beyond neurology, showing interest in both chronic organ disease and patient-centered symptom management.

Site Overview

assignment
13
connected trials
corporate_fare
7
sponsors
science
16
IMPs

Activity Indicator

Last 6 months

3
Trials started
New activity detected vs previous period.
0
Trials started 6–12 months ago
13
Total trials linked
Highly Active
trending_upGrowing+100%
1
1
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 8 therapeutic areas and 13 of 16 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
12
Sponsors (total)
7
Active sponsors
6

Sponsor Network

Top 6 by active trials.

lock +5 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +1 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 271 other sites in The Netherlands

description
Trial volume
13
Outperforms 72% of sites
public
Therapeutic diversity
9areas
Outperforms 77% of sites
groups
Sponsor diversity
7sponsors
Outperforms 69% of sites

Therapeutic Area Benchmark — The Netherlands

Select a therapeutic area to compare against other sites in The Netherlands.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: The Netherlands

Market Share

Country: The Netherlands

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in UMCG

lock Showing 1 of 13 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
An Open-label, Randomized, Three-period, Crossover Study to compare the Pharmacokinetics of GB1211 upon dosing a capsule under fasting condition and a tablet under fasting and fed conditions in healthy volunteers.Galecto Biotech ABPhase INot RecruitingDec 2022Apr 2023

IMP list

lock Showing 1 of 16 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate1Unknown

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.